EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis

John B Tillman iD, Roy W Beck iD, William H Polonsky, Peter Calhoun iD, Thomas Mouse, Ryan Bailey, Jeanne Jacoby, Rakesh Nandan, F Naureen Sheikh, James K Malone

The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · 2134-2146

DOI: 10.1210/clinem/dgae778 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 15.11.2024. Verfasst von John B Tillman und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Affairs, Abbott Diabetes Care, Milpitas, CA 95035, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, Abbott.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

The Bigfoot Unity Diabetes Management System integrates Abbott FreeStyle Libre 2 continuous glucose monitoring (CGM) data into a smart insulin pen cap and mobile app, enabling clinician-directed insulin dose recommendations and real-time alerts.

Objective

The objective was to analyze real-world 6-month glycemic control in a prospective study for individuals using the System for multiple daily insulin injections (MDI).

Methods

We conducted a 6-month analysis from the BURST study (NCT05088265) of individuals with type 1 or type 2 diabetes (T2D). Participants reported baseline demographics, adverse events, and other survey data electronically. Either at-home kit or electronic medical record glycated hemoglobin A1c (HbA1c) data were collected.

Results

Of 102 participants in the per protocol cohort, median age was 59 years, 87% had T2D, 42% used CGM previously, 62% were White non-Hispanic, and 59% female. Mean HbA1c decreased from 9.1 ± 1.7% at baseline to 8.0 ± 1.2% at 6 months (mean difference −1.1%, 95% CI −1.4 to −0.8, P < .001). At 6 months, time in range (70-180 mg/dL), time at < 70 mg/dL, and time at < 54 mg/dL were 56 ± 23%, 1.0 ± 1.4%, and 0.04 ± 0.14%, respectively. Six severe hypoglycemia events occurred in 4 participants (none System-related) and no diabetic ketoacidosis events occurred in the per protocol cohort.

Conclusion

In this study primarily of older adults with T2D using MDI, durable glycemic improvement occurred using the System at 6 months, with the frequency of hypoglycemia being substantially below established targets of < 4% and < 1% for time below 70 and 54 mg/dL, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Glycemic ControlHypoglycemic AgentsInsulinAdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseBlood Glucose Self-MonitoringGlycated HemoglobinHypoglycemiaProspective Studies

Stichwörter der Autor:innen

connected pencontinuous glucose monitormultiple daily injectionsreal-world evidencesmart pen cap

Substanzen

Blood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulin

Autor:innen und Institutionen

  • Department of Clinical Affairs, Abbott Diabetes Care, Milpitas, CA 95035, USA.
  • Jaeb Center for Health Research, Tampa, FL 33647, USA.
  • Behavioral Diabetes Institute, San Diego, CA 92121, USA.
  • Department of Fluorescence Imaging, Intuitive, Sunnyvale, CA 94086, USA.

ORCID-Profile: John B Tillman, Roy W Beck, Peter Calhoun

Förderung

  • NIDDK NIH HHS
  • Abbott

Zitieren

APA

Tillman, J. B., Beck, R. W., Polonsky, W. H., Calhoun, P., Mouse, T., Bailey, R., Jacoby, J., Nandan, R., Sheikh, F. N., & Malone, J. K. (2025). Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis. The Journal of Clinical Endocrinology & Metabolism, 110(8), 2134-2146. https://doi.org/10.1210/clinem/dgae778

Vancouver

Tillman JB, Beck RW, Polonsky WH, Calhoun P, Mouse T, Bailey R, et al. Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):2134-2146. doi:10.1210/clinem/dgae778

BibTeX
@article{Tillman2025,
  author = {Tillman, John B and Beck, Roy W and Polonsky, William H and Calhoun, Peter and Mouse, Thomas and Bailey, Ryan and Jacoby, Jeanne and Nandan, Rakesh and Sheikh, F Naureen and Malone, James K},
  title = {Observed Glycemic and Psychosocial Benefits in the Prospective Bigfoot Unity Real World Study: A 6-Month Analysis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {8},
  pages = {2134--2146},
  doi = {10.1210/clinem/dgae778}
}
Kostenlos starten →